Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company's Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type "B" or "End of Phase 2" meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA. "This CMC approval represents a revolutionary set of 'firsts'," said Dr. Isaac Cohen, Bionovo's Chairman and Chief Executive Officer...
More...
More...